Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.46 |
| ▸ | ITGAL | P20701 | 4/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.46 |
| ▸ | SMO | Q99835 | 3/20 | 0.46 |
| ▸ | NCF1 | P14598 | 2/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932455 | 0.96 | ITGB2 (0.49) | MEN1KMT2AITGB2ITGALICAM1 | |
| SCHEMBL9932266 | 0.90 | MEN1 (0.58) | MEN1KMT2AGRM2 | |
| SCHEMBL9968327 | 0.89 | MEN1 (0.48) | MEN1KMT2ASMOGRM2HDAC1 | |
| SCHEMBL9932994 | 0.89 | MEN1 (0.46) | MEN1KMT2AITGB2ITGALICAM1 | |
| SCHEMBL9932684 | 0.89 | ALDH1A1 (0.46) | MEN1KMT2ASMOGRM2HDAC1 | |
| SCHEMBL9931840 | 0.85 | SMO (0.45) | MEN1KMT2AITGB2ITGALICAM1 | |
| SCHEMBL9932662 | 0.85 | ITGB2 (0.44) | MEN1KMT2AITGB2ITGALICAM1 | |
| SCHEMBL9968309 | 0.84 | MEN1 (0.55) | MEN1KMT2AGRM2 | |
| SCHEMBL9968330 | 0.84 | MEN1 (0.55) | MEN1KMT2AGRM2 | |
| SCHEMBL9932249 | 0.83 | HSD11B1 (0.48) | MEN1KMT2ASMOGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | MEN1 1168/4885KMT2A 310/4885ITGB2 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.